Literature DB >> 26011491

Haematological cancer: Bortezomib in MCL--new standard of care or just another option?

Martin Dreyling1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26011491     DOI： 10.1038/nrclinonc.2015.101

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  6 in total

1.  Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  M Dreyling; C Geisler; O Hermine; H C Kluin-Nelemans; S Le Gouill; S Rule; O Shpilberg; J Walewski; M Ladetto
Journal:  Ann Oncol       Date:  2014-09       Impact factor: 32.976

2.  Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.

Authors:  Bertrand Coiffier; Weimin Li; Erin D Henitz; Jayaprakash D Karkera; Reyna Favis; Dana Gaffney; Alice Shapiro; Panteli Theocharous; Yusri A Elsayed; Helgi van de Velde; Michael E Schaffer; Evgenii A Osmanov; Xiaonan Hong; Adriana Scheliga; Jiri Mayer; Fritz Offner; Simon Rule; Adriana Teixeira; Joanna Romejko-Jarosinska; Sven de Vos; Michael Crump; Ofer Shpilberg; Pier Luigi Zinzani; Andrew Cakana; Dixie-Lee Esseltine; George Mulligan; Deborah Ricci
Journal:  Clin Cancer Res       Date:  2013-04-02       Impact factor: 12.531

3.  Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

Authors:  Tadeusz Robak; Huiqiang Huang; Jie Jin; Jun Zhu; Ting Liu; Olga Samoilova; Halyna Pylypenko; Gregor Verhoef; Noppadol Siritanaratkul; Evgenii Osmanov; Julia Alexeeva; Juliana Pereira; Johannes Drach; Jiri Mayer; Xiaonan Hong; Rumiko Okamoto; Lixia Pei; Brendan Rooney; Helgi van de Velde; Franco Cavalli
Journal:  N Engl J Med       Date:  2015-03-05       Impact factor: 91.245

Review 4.  Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

Authors:  Paul G Richardson; Jacob P Laubach; Nikhil C Munshi; Kenneth C Anderson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

5.  Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

Authors:  A Goy; S H Bernstein; B S Kahl; B Djulbegovic; M J Robertson; S de Vos; E Epner; A Krishnan; J P Leonard; S Lonial; S Nasta; O A O'Connor; H Shi; A L Boral; R I Fisher
Journal:  Ann Oncol       Date:  2008-12-12       Impact factor: 32.976

6.  Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.

Authors:  Sabrina Manni; Alessandra Brancalion; Elisa Mandato; Laura Quotti Tubi; Anna Colpo; Marco Pizzi; Rocco Cappellesso; Fortunato Zaffino; Speranza Antonia Di Maggio; Anna Cabrelle; Filippo Marino; Renato Zambello; Livio Trentin; Fausto Adami; Carmela Gurrieri; Gianpietro Semenzato; Francesco Piazza
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240
  6 in total
  1 in total

1.  Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study.

Authors:  Gregor Verhoef; Tadeusz Robak; Huiqiang Huang; Halyna Pylypenko; Noppadol Siritanaratkul; Juliana Pereira; Johannes Drach; Jiri Mayer; Rumiko Okamoto; Lixia Pei; Brendan Rooney; Andrew Cakana; Helgi van de Velde; Franco Cavalli
Journal:  Haematologica       Date:  2017-02-09       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.